Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Almost seems like a pitch for M and A
ignatiousrielly,
I know of no pumpers on this or any other AVXL discussion board.
Exactly who have you been disparaging in comparing this someone to "kund"
Good luck and GOD bless,
I’m sure the majority of the board could care less what your doom and gloom thoughts are.
There’s still the entire week for them to PR something.
Heck, they may even PR something juicy with “further details” at “name the conference or date”
EXCELLENT VIDEO!!!
VERY WELL DONE!!!
Good luck and GOD bless,
Thanks 3T and LTB! Decades of black box complicated shotgun approaches made into a simple easy to understand presentation.
WGT
Here is the mirror opposite of the pumper that some people complain about. A dedicated idiot. Impressive.
from TTTsv66.https://stkt.co/4xu4swMu
17M short if great a peer review is release i don't believe there be enough shares to borrow to short because more institutionals will piling in as well also it going to hard to cover i don't think shorty will be that dump and EMA submiting is around the corner as well.i think this CONF will be difference from the last time.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
And your point is? There is no guarantee Misleading and company are attending AAIC this year. There is no PR. Normally, he likes to pump it 15-25 days before, and we are getting closer with still no PR. I have my doubts they are not attending and presenting AAIC.
Just remember….Anything they DO present, the AF of the world will get it before it’s public thanks to his “reporter” status.
i think we may get one or two PR next week.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
they skip 2023 AAIC i don't think they going to presenting the same stuff again.you can bank on it.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
JJ---"Does Anavex know if and when"---if they do know they are keeping it top secret--not telling anyone---continue to "wait and see" !!! If they know -would be nice to inform the shareholders !!!! Misslings middle name--"under the radar"--"silence is golden" !!!
You can see why the simufilam p2 results could be considered problematic.
Thanks. Much appreciated.
Do you have a link for this "FDA presentation" of an OLE?
TIA
Take a look at this recent peer reviewed paper. It took 9 months from being accepted to being published. That does not include the time it took to actually write it. It’s shown at the bottom of the article.
Received
24 October 2023
Accepted
29 May 2024
Published
17 July 2024
https://www.nature.com/articles/s41586-024-07624-5
Does Anavex know if and when the peer review is coming out?
If not - Rehash what is already known and sprinkling some extra details that don’t violate peer review data embargo.
If it comes out before. Great - Lots to present
Without knowing, it seems Marwan would need to have two different presentations ready.
Hope we can generate some excitement.
Because it has not yet been approved and it is a novel approach to CNS disease. Oh yeah, there is a large short position.
If drug works then why stock is stuck at this level?
Data and analysis have already been released. More will come from the peer-reviewed paper but pretty sure you and everyone else already knows 2-73 works for AD to some degree (45% decrease in progression over 48 weeks.)
Yep, he is busy backing up imaginary data
We have the Safety. Missing needs to release
Data NOW to show Efficacy or lack thereof.
https://amp.theguardian.com/society/2024/mar/24/alzheimers-breakthrough-drugs-medicine-donanemab-aducanumab-lecanemab
All honest longs here know the answer is NO. We have attempted to warn posters about P&D schemes by certain players. I am a long term AVXL holder & know the game some play.
Although knowing missling, he probably has a back up to the back up:)
I hope none of our data was on a Microsoft computer or secured by crowdstrike
" Cloudstrike screwup " sb "Crowdstrike"oops !
Steady T
I strongly agree with that! This knocked everyone off their rocking chair...notice that the $VIX shot up big pointing to this spreading to the general market, too!
Hopefully, this will not create a lasting effect after such a strong market showing in recent days with such a reversal as on Friday.
I actually thought $AVXL did "OK" in that the pullback did drop to the breakout level of the 200 day sma as a back test, so it held up even with that; my forecast of a strong day Friday was a miss on my part.....My Bad. no "Friday, Friday" for me
The Cloudstrike screwup had a major effect on the market.
O.T. already approved huh.
There HAS to be something better to do than monitor message boards on a Friday night
It is an Open Label Extension to the primary trial.
Since it is open label and the population in the OLE trial is self selected the RA don't give the trial much value in terms of proving efficacy.
What they do value is the safety aspect of the longer exposure to the drug.
Whether the company has seen the data during the OLE or not until the end of the OLE makes little difference. The data doesn't change either way.
With your logic, the courts would be flooded with millions of cases. Misleading lies through his teeth; the guy has no morals when he says anything during conference calls. He just blabbers whatever comes to his mouth at that time—no strategy, no plan, just spouting out whatever comes to his mind.
Not sure why he is the CEO, but I know why he is still CEO: his college buddies on the board. It’s all monkey business.
Yes the TOTAL for today 592K shares and that includes around 80K that sold as MOC. So trading was light today from our normal average trades.
John k9uwa
Hope DOJ and SEC sue Misleading for his false statements and promises over the last 10 years. The guy deserves orange suits. In fact, he deserves jail time more than SAVA executives. MF said mid-2024 AD RNA data and Rett trial design would be PR'd, and we already crossed the midpoint but still have no information, also there is no guarantee of AAIC attendance, no PR till date
That is a good question.
I'd guess that the subjects on placebo will have to go through the same titration process as the original trial subjects to get to their max dose.
Are you ever gonna stop?
" maybe even 10 million shares bought."--another great (NOT) call from george---give it up george !!
Your predictions are worse than a coin toss by an order of magnitude. On the bright side, that's no worse than tarot123.
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
Alan K Percy 1 , Jeffrey L Neul 2 , Timothy A Benke 3 , Elizabeth M Berry-Kravis 4 , Daniel G Glaze 5 , Eric D Marsh 6 , Amy M Barrett 7 , Di An 8 , Kathie M Bishop 8 , James M Youakim 9
Affiliations collapse
Affiliations
1 Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
2 Department of Pediatrics, Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, USA.
3 Department of Pediatrics, Children's Hospital of Colorado/University of Colorado School of Medicine, Aurora, CO, USA.
4 Departments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, IL, USA.
5 Department of Pediatrics and Neurology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, USA.
6 Division of Child Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
7 Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
8 Acadia Pharmaceuticals, Inc., San Diego, CA, USA.
9 Acadia Pharmaceuticals, Inc., San Diego, CA, USA. Electronic address: jyouakim@acadia-pharm.com.
PMID: 39025065 DOI: 10.1016/j.medj.2024.06.007
Abstract
Background: Trofinetide was approved for the treatment of Rett syndrome (RTT) in patients aged =2 years based on the results of the 12-week, randomized, phase 3 LAVENDER study. In LILAC, a 40-week, open-label extension study of LAVENDER, trofinetide continued to improve the symptoms of RTT, with a similar safety profile as LAVENDER. Here, we report long-term safety and efficacy results of LILAC-2, a 32-month, open-label extension study.
Methods: Females aged 5-22 years who completed LILAC were eligible to enter LILAC-2. Safety and tolerability were assessed with the incidence of adverse events (AEs). Efficacy was assessed with Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression-Improvement (CGI-I) scores. Caregiver interviews explored the patient's experience with RTT and the efficacy of trofinetide during study participation.
Findings: In total, 77 participants were enrolled in LILAC-2. The most common AEs were diarrhea (53.2%), COVID-19 (27.3%), and vomiting (19.5%). The mean (standard error [SE]) change in RSBQ score from LAVENDER baseline to week 104 of LILAC-2 was -11.8 (2.45). The mean (SE) CGI-I score from LILAC baseline to week 12 of LILAC-2 was 3.1 (0.10). Most caregivers (96%; n = 24/25) were satisfied or very satisfied with the benefits of trofinetide.
Conclusions: Long-term treatment with trofinetide continued to improve RTT symptoms, without new safety concerns. Caregivers reported satisfaction with trofinetide related to improvements that were meaningful for their child and themselves.
https://www.cell.com/med/fulltext/S2666-6340(24)00253-8?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666634024002538%3Fshowall%3Dtrue
Good luck and GOD bless,
That information is not in the clinical trials record available to the public:
https://clinicaltrials.gov/study/NCT04314934?intr=ANAVEX2-73&rank=1
Each of the participants in the Anavex OLE Alzheimer's study are taking the maximum tolerable dose for each participant.
Good luck and GOD bless,
Correct me if I'm wrong, doesn't all of the patients that participate in the OLE receive the exact same dosage of blarcamesine?
Was able to dnargle up a few shares at yhe close
Lol! That was one hell of short squeeze Georgejll - are you happy?
george, you were only 4.3 MILLION SHORT on your prediction.
But still, george, there can't be a short squeeze if there are no sellers ... at $6 bucks or less.
Well that was some serious short squeeze today LOL....the man who promised 5-10 MILLION shares to be BOUGHT today fell a tad short.....GEORGIE the dreamer has topped even himself today missing by millions and still batting 1000, always wrong
SHORT SQUEEZE on AVXL stock!!!
Good luck and GOD bless,
Thank you abew, sorry for the late reply(s). All good on this front just patiently waiting for more good news.
Tred
Followers
|
1079
|
Posters
|
|
Posts (Today)
|
13
|
Posts (Total)
|
468201
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |